Dr. Karageozian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
19671 Beach Blvd
Suite 400
Huntington Beach, CA 92648Phone+1 714-842-0651Fax+1 714-848-7826- Is this information wrong?
Summary
- Dr. Karageozian is an industry veteran in ophthalmic drug development with more than 25 years of experience building, leading, and fundraising companies in the ophthalmic pharmaceutical space.
An ophthalmic surgeon by training with 18 years of cataract and anterior segment practice, Dr. Karageozian is also the co-founder of three ophthalmic biotech companies since 1993, including ISTA Pharmaceuticals, Inc., Vitreoretinal Technologies, Inc., and Allegro Ophthalmics, LLC. He has been the inventor or co-inventor of numerous ophthalmic pharmaceuticals with more than 82 patents issued on his drug discoveries. His co-inventions include some of the first enzymatic, osmotic, and integrin-based treatments for the eye and some of the earliest work in intravitreal injections (Vitrase®).
Dr. Karageozian has been instrumental in securing over $240M in aggregate venture and institutional capital and corporate partnerships for these companies.
Education & Training
University of California (Irvine)Residency, Ophthalmology, 1997 - 2000
St Mary Medical CenterInternship, Internal Medicine, 1995 - 1996
Tufts University School of MedicineClass of 1995
Certifications & Licensure
CA State Medical License 1996 - 2024- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Publications & Presentations
PubMed
- 3 citationsImpact of Baseline Quantitative OCT Features on Response to Risuteganib for the Treatment of Dry Age-Related Macular Degeneration: The Importance of Outer Retinal Inte...Joseph R Abraham, Glenn J Jaffe, Peter K Kaiser, Stephanie J Chiu, Jessica Loo, Sina Farsiu, Laurens Bouckaert, Vicken Karageozian, Melvin Sarayba, Sunil K Srivastava,...> ;Ophthalmology. Retina. 2022 Nov 1
- 1 citationsThe Transcriptome Profile of Retinal Pigment Epithelium and Müller Cell Lines Protected by Risuteganib Against Hydrogen Peroxide Stress.Zixuan Shao, Marilyn Chwa, Shari R Atilano, John Park, Hampar Karageozian, Vicken Karageozian, M Cristina Kenney> ;Journal of Ocular Pharmacology and Therapeutics. 2022 Sep 1
- 7 citationsDifferential effects of risuteganib and bevacizumab on AMD cybrid cells.Kevin Schneider, Marilyn Chwa, Shari R. Atilano, Zixuan Shao, John Y Park, Hampar L. Karageozian, Vicken H. Karageozian, M. Cristina Kenney> ;Experimental Eye Research. 2021 Feb 1
- Join now to see all
Press Mentions
U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry Age-Related Macular DegenerationAugust 3rd, 2021- Allegro Ophthalmics Announces Positive Results of Vehicle-Controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye DiseaseJuly 24th, 2021
- William J. Link, PhD, Named Chairman of Allegro Ophthalmics’June 22nd, 2021
- Join now to see all
Professional Memberships
- Fellow
Other Languages
- Armenian
Hospital Affiliations
Hoag Memorial Hospital PresbyterianNewport Beach, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
